Cas:13455-00-0 diiodophosphanyl(diiodo)phosphane manufacturer & supplier

We serve Chemical Name:diiodophosphanyl(diiodo)phosphane CAS:13455-00-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

diiodophosphanyl(diiodo)phosphane

Chemical Name:diiodophosphanyl(diiodo)phosphane
CAS.NO:13455-00-0
Synonyms:tetraiododiphosphane;MFCD00011526;Phosphorus iodide;Diphosphorus tetraiodide;Hypodiphosphorous tetraiodide;tetraiododiphosphine;Diphosphorous tetraiodide;EINECS 236-646-7;Diphosphortetraiodid
Molecular Formula:I4P2
Molecular Weight:569.56500
HS Code:

Physical and Chemical Properties:
Melting point:124-127ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:27.18000
Exact Mass:569.56500
LogP:5.26520

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3260 8
Packing Group:II


Contact us for information like tetraiododiphosphane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Diphosphortetraiodid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tetraiododiphosphine Use and application,tetraiododiphosphane technical grade,usp/ep/jp grade.


Related News: The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems. Nonylcyclohexane manufacturers Biogen hiked its revenue guidance for the year, saying it expects total sales of $10.65 billion to $10.85 billion this year. That’s up from its previous estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” revenue from Aduhelm in 2021, ramping up thereafter, the company said. Ronacaleret suppliers The PLI scheme aims to accelerate indigenous manufacturing of critical bulk drugs for which India is dependent on imports. Under this scheme government offered incentives varying between 10 to 20%. Octadecanol vendor & factory.